CGONCGONHealthcare · Biotechnology

CGON Stock Forecast: CG Oncology, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$79
−6.89% on the day

The 14 Wall Street analysts covering CG Oncology, Inc. hold a median 12-month price target of $100 — +26.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 16 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.6B
Ticker Nerd rank
36/ 100
Median analyst target
$100
Analysts covering
14
Revenue$1.2M
Operating income−$86.4M
Net income−$79.1M
Free cash flow−$46.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.7%
1M
+31.9%
YTD
+90.1%
1Y
+91.4%
From 52W high
−6.9%
From 52W low
+111.2%
$37
$85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CG Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
36/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Revisions
88
Growth
63
Accruals
30
Issuance
30
Volatility
29
Value
26
Size
18
Quality
10

Momentum (92): The shares have been drifting up relative to others.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CGON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26CGONHigh $150Median $100Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $80Median $100High $150

The green dot is the last close — the median target sits +26.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
9 Nov 2026GuggenheimMaintainsBuy$90 → $89
6 Nov 2026WedbushMaintainsOutperform$80 → $84
7 Aug 2026Piper SandlerMaintainsOverweight$82 → $85
7 Aug 2026Piper SandlerMaintainsOverweight—
7 Aug 2026RBC CapitalMaintainsOutperform$81 → $79
7 Aug 2026RBC CapitalMaintainsOutperform—
7 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026Truist SecuritiesMaintainsBuy$82 → $85
19 May 2026Wolfe ResearchInitiatesPeer Perform—
19 May 2026Wolfe ResearchInitiatesPeer Perform—
18 May 2026HC Wainwright & Co.ReiteratesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy$100
14 May 2026Truist SecuritiesReiteratesBuy—
14 May 2026Truist SecuritiesReiteratesBuy$77 → $82
11 May 2026JP MorganMaintainsOverweight—
11 May 2026RBC CapitalMaintainsOutperform—
11 May 2026Truist SecuritiesReiteratesBuy—
11 May 2026WedbushMaintainsOutperform—
27 Apr 2026RBC CapitalMaintainsOutperform—
17 Apr 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CGON appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CGON vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, CG Oncology, Inc. returned +91.4% against +11.2% for the S&P 500, dividends included.

CGON vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Jan 26Apr 26Jul 26Oct 26CGONS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

CG Oncology, Inc. (CGON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−40.7×

Cheaper than 98% of US stocks

Price / sales
1228.1×

Cheaper than 1% of US stocks

Price / book
7.6×

Cheaper than 12% of US stocks

EV / EBITDA
−25.3×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
−3.7%

Higher than 22% of US stocks

Earnings growth (YoY)
1982.7%

Higher than 99% of US stocks

Gross margin
−239.2%

Higher than 1% of US stocks

Operating margin
−4293.5%

Higher than 3% of US stocks

Net margin
−15.0%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−28.3%

Higher than 28% of US stocks

Return on assets
−18.6%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CG Oncology, Inc. (CGON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CG Oncology, Inc. has a market value of $7.6B and an enterprise value of $6.6B.

  • Revenue in the twelve months to 30 June 2026: $6.2M. The latest quarter shrank 3.7% year on year.

  • Net income over the same four quarters: −$224.4M, a −3602.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$179.3M.

  • Shares outstanding: 88.3M.

  • Trailing P/E: −40.7×; forward P/E: −29.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CG Oncology, Inc. employs 142 people — $44K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

CGON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGONCG Oncology, Inc.$7.6B36
CORTCorcept Therapeutics, Inc.$7.4B75
RYTMRhythm Pharmaceuticals, Inc.$7.4B84
CYTKCytokinetics, Inc.$7.4B61
AXSMAxsome Therapeutics, Inc.$7.1B73
PTGXProtagonist Therapeutics, Inc.$8.0B89
TWSTTwist Bioscience Corp.$6.9B62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CG Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGON news & analysis

CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds

Benzinga · 16 Nov 2026positive

CG Oncology announced positive topline results from its Phase 3 PIVOT-006 trial on Monday. CEO Arthur Kuan described the results as a defining milestone for the company.

Why it matters — The trial results are a notable company update for investors and others following CG Oncology.

2 Cancer-Drug Developers Seeing Unusual Options Volume

Schaeffers Research · 16 Nov 2026neutral

Unusual options activity was reported for Summit Therapeutics and CG Oncology, which were moving in opposite directions after major clinical and regulatory developments. The excerpt does not specify CG Oncology’s direction or the underlying developments.

Why it matters — The report flags unusual options activity involving CG Oncology, but provides no details about the company-specific catalyst or direction.

CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out

Investors Business Daily · 16 Nov 2026positive

CG Oncology said its experimental bladder cancer treatment reduced the risk of recurrence by 68%. The report also said the stock broke out.

Why it matters — CGON watchers may follow the reported recurrence-risk reduction and the associated stock movement.

PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)

GlobeNewsWire · 16 Nov 2026positive

CG Oncology reported that its PIVOT-006 Phase 3 trial of cretostimogene demonstrated a statistically significant reduction in recurrence risk for intermediate-risk and high-grade Ta NMIBC. The reported hazard ratio was 0.32 (95% CI: 0.23–0.45), corresponding to a 68% reduction in recurrence risk.

Why it matters — The reported Phase 3 recurrence-free survival results are relevant to CGON watchers tracking clinical progress for cretostimogene.

FAQ

Frequently asked questions about CGON stock

What is the CGON stock price forecast for 2026-2027?

The 14 Wall Street analysts covering CG Oncology, Inc. have a median 12-month price target of $100, with estimates ranging from $80 to $150. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGON stock a buy right now?

Of the 14 analysts covering CG Oncology, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CG Oncology, Inc. 36 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGON?

As at 16 Nov 2026, CG Oncology, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will CGON stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +26.7% from the last close, and Ticker Nerd's factor model ranks CG Oncology, Inc. 36 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGON stock forecast for 2030?

No analyst covering CG Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $150 over the next 12 months.

How has CGON stock performed over the past year?

CG Oncology, Inc. returned +91.4% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CG Oncology, Inc. do?

CG Oncology Inc. is a clinical biopharmaceutical company focused on bladder cancer, with an emphasis on bladder-sparing therapies for patients with non-muscle invasive disease.

What is the latest news on CGON?

The most recent item we track (Benzinga, 16 Nov 2026): "CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds". CG Oncology announced positive topline results from its Phase 3 PIVOT-006 trial on Monday. CEO Arthur Kuan described the results as a defining milestone for the company.

Company

About CG Oncology, Inc.

CG Oncology Inc. is a clinical biopharmaceutical company focused on bladder cancer, with an emphasis on bladder-sparing therapies for patients with non-muscle invasive disease. The company’s lead product candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy designed to act directly within the bladder and engage the immune system against tumors. CG Oncology is developing this therapy across multiple current clinical programs for high-risk and intermediate-risk bladder cancer settings, including combination studies with other oncology treatments. The company’s work centers on addressing unmet needs in urologic oncology through localized treatment approaches that aim to preserve the bladder while targeting disease at the source.

CEO Mr. Arthur Kuan · 142 employees · United States · https://cgoncology.com